单唾液酸四己糖神经节苷酯治疗新生儿缺氧缺血性脑病90例  

Evaluation of clinical effect of neonatal hypoxic-ischemic encephalopathy on 90 cases of monosialoganglioside

作　　者：郑磊[1] 邵斌[1] 任艳丽[1] 胡生海[1] 

机构地区：[1]郑州大学第三附属医院药剂科,郑州450052

出　　处：《中国实用神经疾病杂志》2008年第7期54-55,共2页Chinese Journal of Practical Nervous Diseases

摘　　要：目的研究单唾液酸四己糖神经节苷酯(GM1)静滴治疗新生儿缺氧缺血性脑病(HIE)疗效。方法将90例HIE患儿随机分为观察组和对照组,每组45例,均予常规治疗,观察组加用GM1。观察和记录2组临床症状、体征恢复情况和新生儿行为神经测定(NBNA)评分。结果应用GM1治疗新生儿HIE对改善HIE所致的远期神经系统发育障碍有较好的疗效。结论在常规治疗基础上加用GM1是目前治疗中重度HIE较理想的方法。Objective To investigate the therapeutic effect of monosialoganglioside （GM1） treating neonatal hypoxic-ischemic encephalopathy （HIE）. Methods 90 cases of patients with HIE were divided into experimental group （ n= 45） and routine treatment group （ n=45 ） randomly. Patients in pidotimod group were given additional treatment of monosialoganglioside on the basis of routine treatment. Clinical symptoms, status of physical signs recovery and neonatal behavioral neurological assessment （NBNA） were observed and recorded. Results Monosialoganglioside had better curative effect on the neurodevelopmental impairment and disability caused by HIE. Conclusion Given additional treatment of monosialoganglioside on the basis of routine treatment is a desirable way to therapy moderate or severe HIE.

关 键 词：新生儿缺氧缺血性脑病 单唾液酸四己糖神经节苷酯 疗效观察 

分 类 号：R722.1[医药卫生—儿科]